

NEW TEST ANNOUNCEMENT

NOTIFICATION DATE: March 18, 2011 **EFFECTIVE DATE:** March 21, 2011

ISLET ANTIGEN 2 (IA-2) ANTIBODY, SERUM #89588

USEFUL FOR:

- Clinical distinction of type 1 from type 2 diabetes mellitus
- Identification of individuals at risk of type 1 diabetes (including high-risk relatives of patients with diabetes)
- Prediction of future need for insulin treatment in adult-onset diabetic patients

METHODOLOGY: Radioimmunoprecipitation

REFERENCE VALUES: < or =0.02 nmol/L

SPECIMEN REQUIREMENTS:

Container/Tube: Plain, red-top tube or serum gel tube

Specimen Volume: 1 mL

CAUTIONS: Negative results do not exclude the diagnosis of or future risk for type 1 diabetes mellitus. The risk of developing type 1 diabetes may be stratified further by testing for: 1) antibodies targeting insulin, GAD65, and zinc transporter 8 (ZnT8) and 2) HLA genetic markers. Careful monitoring of hyperglycemia is the mainstay of determining the requirement for insulin therapy.

NOTE: Test 57130 – ICA-512 Autoantibodies to Esoterix will become obsolete on April 21, 2011.

LIST FEE: \$228.30

CPT CODE: 86341

ANALYTIC TIME: 3 days/neg, 5 days/pos DAY(S) SET-UP: Tuesday, Thursday; 10:00 a.m.

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager or Steven Monson, MML Laboratory Technologist Resource Coordinator Telephone: 800-533-1710